A Hidden Opponent: Should Athletes Need Pneumococcal Protection?
European Medical Specialist Review · 24.04.2026
DOI: 10.67452/emsr.2026.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Medical Specialist Review, online erschienen am 24.04.2026. Verfasst von Deepak Nagra und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Elite athletes are increasingly recognised as a population vulnerable to respiratory infections due to intense physical exertion, international travel, close-contact living environments, and exercise-induced immune dysregulation. Despite these recognised risks, pneumococcal vaccination is not routinely recommended for athletes within current United Kingdom travel immunisation guidance.
Methods
This commentary reviews existing evidence regarding respiratory infections among athletes, examines the immunological mechanisms that may increase susceptibility to pneumococcal disease, and evaluates current evidence supporting targeted vaccination strategies in elite sporting populations.
Results
Respiratory infections occur at an estimated rate of 4.7 infections per 1000 athlete days, with higher rates observed among non-elite athletes. Major international sporting events, including the Olympic and Paralympic Games, have reported substantial numbers of respiratory tract infections among participants. Studies have demonstrated exercise-related immune dysregulation, including reduced circulating memory T cells and upper airway dysbiosis, potentially increasing susceptibility to bacterial pathogens such as Streptococcus pneumoniae. Similar patterns of disease transmission have been observed in military cohorts exposed to comparable close-contact environments. The recent introduction of the 20-valent pneumococcal conjugate vaccine (PCV20) may provide expanded protection against emerging pneumococcal serotypes associated with antimicrobial resistance and outbreak potential.
Conclusion
Elite athletes represent a potentially under-recognised risk group for pneumococcal disease. Incorporating pneumococcal vaccination into pre-travel health assessments for athletes may offer an important preventive strategy, particularly for individuals participating in prolonged international travel, close-contact sporting environments, or intensive training schedules. Further research is needed to better characterise bacterial respiratory infections in athletes and inform future evidence-based vaccination policy.
Zitieren
APA
Nagra, D., Nouri, B., Blake, T., Adas, M., Russell, M., & Galloway, J. (2026). A Hidden Opponent: Should Athletes Need Pneumococcal Protection?. European Medical Specialist Review. https://doi.org/10.67452/emsr.2026.002
Vancouver
Nagra D, Nouri B, Blake T, Adas M, Russell M, Galloway J. A Hidden Opponent: Should Athletes Need Pneumococcal Protection?. European Medical Specialist Review. 2026. doi:10.67452/emsr.2026.002
BibTeX
@article{Nagra2026,
author = {Nagra, Deepak and Nouri, Bako and Blake, Tim and Adas, Maryam and Russell, Mark and Galloway, James},
title = {A Hidden Opponent: Should Athletes Need Pneumococcal Protection?},
journal = {European Medical Specialist Review},
year = {2026},
doi = {10.67452/emsr.2026.002}
}
EUVIMED